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HIGHLIGHTS 
 Roller bottle sustain the continuous production of Rabies Virus-Like 
Particles (RV-VLP). 
 Roller bottle produced RV-VLPs induce a specific antibody response in 
mice. 
 RV-VLPs without adjuvant addition induce high titer of long-lasting 
neutralizing antibodies. 
 Potency test of the vaccine candidate demonstrate protection against 
rabies virus challenge.  




Rabies is a neglected disease with an estimated annual mortality of 55,000 
human deaths, affecting mainly low-income countries. Over 95% of these 
cases result from virus transmission through the bite of infected dogs and for 
this reason there is a real need for a cheap and effective rabies veterinary 
vaccine to be used in mass vaccination campaigns. In this work, we describe 
the establishment of a simple platform for the production of a virus-like 
particles based rabies vaccine using mammalian cells and roller bottles as 
culture system. Adherent cells were cultured during more than 15 days and 
VLPs were continuously produced and secreted to the culture supernatant. 
Immunogenicity and protective efficacy of VLPs were tested through rabies 
virus neutralizing antibody test and NIH potency test. These viral particles 
induced high titer of long lasting neutralizing antibodies and protected mice 












promising platform for the production of a new generation and virus-free 
rabies vaccine candidate for veterinary applications. 
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Introduction 
Although effective rabies vaccines have been available since 1885 (Briggs, 
2012), human deaths from rabies are still an important health issue worldwide 
(WHO Expert et al., 2013). As dog bites are the main cause of rabies 
transmission to human beings, the priority is to reduce the burden of human 
rabies by controlling dog rabies through diverse methodologies where stray 
dogs care and mass vaccination campaigns are the central and more cost-
effective activities (Fooks et al., 2017; Hampson et al., 2015; Shwiff et al., 
2013).  
In the case of rabies the “One Health” approach takes central importance to 
achieve the WHO, the World Organization for Animal Health (OIE) and the 
Food and Agriculture Organization of the United Nation (FAO) goal to 
eliminate dog-transmitted human rabies in endemic countries by 2030 
(Wallace et al., 2017). To fulfill this goal, 70% of the dogs have to be 
vaccinated during at least 7 consecutive years, and therefore the demand of 
canine rabies vaccine will be increased. A study estimates that if the 
production remains at the current level there will be a cumulative shortage of 
about 7.5 billion doses in order to meet the demand to achieve dog rabies 
elimination by 2030 (Wallace et al., 2017). This scenario shows the need of 
having more and cheaper sources of veterinary vaccines, mostly for the 
countries were dog rabies is endemic. 
In the last decades many developments of recombinant rabies vaccine 
candidates have been published but, although they demonstrate the induction 
of humoral immune responses, some of those articles do not inform if the 
vaccine candidates are able to confer protection against virus challenge 
(Briggs, 2012; Hicks et al., 2012). Furthermore, those recombinant antigens 
having an effective protective capacity in the proof of concept were not 
assessed in larger production scales. Thus, veterinary vaccines that are 
currently available in the market continue being the classical inactivated 
vaccines containing adjuvant, in most cases aluminium hydroxide, in its 
formulation.  
Previously, our group developed an adherent HEK293 cell clone (adhP2E5) 
that continuously express immunogenic rabies virus-like particles (RV-VLPs) 
to the culture supernatant (Fontana et al., 2015, 2014). The RV-VLPs were 
completely characterized and we showed that they are circular enveloped 
viral particles containing the rabies virus glycoprotein (G) in the surface. In 
this work we studied the use of these stable recombinant mammalian cells for 
the establishment of a method for the production of RV-VLPs using roller 












vaccine. This platform is fully applicable to the already available industrial 
facilities, avoids the manipulation of active rabies virus and the use of any 
adjuvant in the formulation, turning cheaper and safer the production of this 
new generation rabies vaccine for the veterinary market. 
 
Materials and methods 
1. Cells and antibodies 
HEK-293 cells were cultured in Dubelcco’s modified Eagle medium (DMEM, 
Gibco) supplemented with 10% fetal calf serum (FCS, Gibco) at 37°C with 
5% CO2.  
Monoclonal antibodies and polyclonal sera, used to detect the rabies virus 
glycoprotein, were produced in our laboratory. Goat anti-mouse AlexaFluor 
488® was purchased from InvitrogenTM (Thermo), polyclonal goat anti-mouse 
immunoglobulins/HRP were purchased from DAKO (Agilent) and the HRP-
streptavidin complex was purchased from Sigma–Aldrich (Merk). The 
inactivated rabies virus vaccine used for the immunization protocol is the 
commercially available veterinary vaccine Rabisin® (Merial). 
 
2. Confocal microscopy 
Cells grown on cover-slips were washed twice in PBS and fixed by incubation 
with 4% paraformaldehyde in PBS for 30 minutes at room temperature. Cells 
were then incubated for 30 minutes at room temperature with a monoclonal 
antibody against G glycoprotein diluted 1:1,000 in PBS, washed three times 
in PBS and incubated with a goat anti-mouse AlexaFluor 488® antibody 
diluted 1:1,000 in PBS. Thereafter, cell nuclei were counterstained with TO-
PRO™-3 Iodide (Thermo) for 30 minutes. Cells were washed three times in 
PBS and the slides were mounted with glycerol for confocal microscopy 
analysis and examined with a Leica–TCS–SP8 confocal microscope (Leica). 
 
3. RV-VLPs production 
To produce RV-VLPs we used the adhP2E5 clone that was previously 
obtained from the original HEK-G cell line (Fontana et al., 2014). Briefly, the 
RV-VLPs expressing cell line was cloned by dilution limit method. Obtained 
clones were analyzed by flow cytometry and adhP2E5 was chosen as the 
producer one, because of the 6-fold increase in the glycoprotein expression 
level when compared with the cell line. The specific RV-VLPs productivity 
was calculated by sandwich ELISA, obtaining a value of rabies glycoprotein 
content of 1.1 × 10−6 IU.cel−1.d−1, between 5 and 6 times higher than the 
productivity of the recombinant cell line with a value of 0.2 × 10−6 IU.cel−1.d−1 
(Fontana et al., 2015). 
In this work, adhP2E5 cells were cultured in 175 cm2 T flasks (Greiner Bio-
One) and harvested at exponential growth phase. 850 cm2 roller bottles 
(CellmasterTM, Greiner Bio-One) were seeded with a 1.5x105 cells.ml-1 
suspension in DMEM supplemented with 10% FCS, reaching a final volume 












(Wheaton) at 0.2 rpm at 37°C in 5% CO2 atmosphere. Medium exchange was 
performed every 48 h during the first 13 days and every 24 h during the last 5 
days. Culture supernatants containing RV-VLPs were pooled, clarified by 
centrifugation at 200 x g for 10 min and then filtered thought a 0.6 μm and 0.2 
μm filtration train. 
 
4. RV-VLPs purification and characterization 
The clarified supernatant was layered over a 30% sucrose cushion and 
centrifuged at 65,000 × g for 3 h at 4°C (Beckman JA.30 rotor, Beckman 
Coulter). The supernatant and sucrose cushion were poured off, the pellet 
was resuspended in RV-VLPs stabilization buffer (50 mM Tris–HCl, 0.15 M 
NaCl, 1.0 mM EDTA, pH 7.4), loaded over a 20–30–40–50% iodixanol 
density gradient (OptiPrepTM, Axis-Shield) and centrifuged at 100,000 × g for 
4 h at 4°C (Beckman JS24.15 rotor, Beckman Coulter). The banded VLPs 
were collected and the buffer was exchanged using 100,000 MWCO 
Amicon® Ultra centrifugal units (Millipore) and RV- VLPs stabilization buffer. 
RV-VLPs were analyzed by negative staining electron microscopy. Purified 
particles were adsorbed to a formvar-coated 300-mesh copper grid for 2 min. 
Excess was removed with filter paper and grids were then negatively stained 
with 2% uranyl acetate for 2 min. Samples were examined using a 
transmission electron microscope (TEM) Jeol JSM-100 CX II (Jeol, Japan) 
and digital images were acquired with a CCD 785 ES1000W camera (Gatan). 
 
5. ELISA sandwich 
The sensitization step was as follows: 96-well micro-plates (Greiner Bio-One) 
were coated by adding in each well 100 µl of a 1:2,000 dilution of rabbit 
polyclonal sera against rabies virus in carbonate buffer pH 9.6 and incubating 
for 1 h at 37°C and over night at 4°C. After six washes (PBS, 0.05% Tween-
20) wells were blocked with 200 µl 2% skim milk in PBS for 1 h at 37°C and 
washed again. Serial 2-fold dilutions of cell culture supernatants were 
prepared (in PBS, 0.05% Tween-20, 0.2% skim milk), distributed (100 µl per 
well) and incubated for 1 h at 37°C. After that, plates were incubated for 1 h 
with a dilution of a biotin-conjugated rabbit polyclonal antibody (diluted 
1:2,000 in PBS, 0.05% Tween-20, 0.2% skim milk) and followed by 1 h 
incubation with HRP-streptavidin complex (Sigma–Aldrich) (diluted 1:15,000 
in PBS, 0.05% Tween-20, 0.2% skim milk). Six washes were performed 
between each step and the reaction was revealed by adding 100 µl per well 
of a chromogenic substrate solution (0.5 mg/ml o-phenylenediamine (Sigma–
Aldrich), 0.5 µl.ml-1 H2O2 30 vol., 50 mM citrate-phosphate buffer, pH 5.3) and 
stopped by adding 50 µl of a 0.5 M sulphuric acid solution. The optical density 
was measured at 492 nm in a spectrophotometer (Labsystems Multiskan®). 
The World Health Organization 6th International Standard for Rabies Vaccine 
(NIBSC) was used as standard. For in vitro assays (such as ELISA or single 
radial immunodiffusion test) the ampoule contains 3.3 IU Pitman Moore 












and the concentration expressed as ELISA Units (EU).ml−1 of glycoprotein 
rabies virus antigen content.  
 
6. Mice immunization and serology 
6.1. Immunization plan 
Female 4–5 week old BALB/c mice were intraperitoneally injected with roller 
produced RV-VLPs preparations without adjuvant addition (Group 1, n=6), 
and boosted on day 7-post primary immunization. Positive control group was 
immunized with a commercially purchased inactivated rabies virus vaccine 
(Group 2, n=7), and boosted on day 7-post primary immunization as well. For 
measurement of humoral response parameters blood samples were collected 
on days 17, 47, 147 and 210. Pre-immunized reference sera were collected 
prior injection. 
 
6.2. Total specific antibody titer determination (indirect ELISA) 
96-well micro-plates (Greiner Bio-One) were coated by adding in each well 
100 µl of an appropriate dilution of RV-VLPs preparation in carbonate buffer 
pH 9.6 and incubating for 1 h at 37°C and overnight at 4°C. After six washes 
(PBS, 0.05% Tween-20), wells were blocked with 200 µl 2% skim milk in PBS 
for 1 h at 37°C and washed again. Serial 2-fold dilutions of sera samples 
were prepared (in PBS, 0.05% Tween-20, 0.2% skim milk), distributed 100 µl 
per well and incubated for 1 h at 37°C. After that, plates were incubated for 1 
h with HRP-conjugated rabbit anti-mouse immunoglobulins (diluted 1:2,000 in 
PBS, 0.05% Tween-20, 0.2% skim milk). Six washes were performed 
between each step and the reaction was revealed by adding 100 µl per well 
of a chromogenic substrate solution (0.5 mg/ml o-phenylenediamine (Sigma-
Aldrich), 0.5 µl.ml-1 H2O2 30 vol., 50 mM citrate-phosphate buffer, pH 5.3). 
The reaction was stopped by adding 50 µl of 0.5 M sulphuric acid solution 
and the optical density was measured at 492 nm in a spectrophotometer 
(Labsystems Multiskan®). OD 492 nm values exceeding the mean + 2 S.D. of 
negative controls (basal mice sera) were considered as positive. 
 
6.3. Rabies virus neutralizing antibody (RVNA) determination 
To analyse the presence of RVNA in sera of vaccinated animals, an in vitro 
assay using recombinant lentivirus pseudotyped with the rabies glycoprotein 
and carrying the Green Fluorescent Protein sequence (GFP) was performed, 
as was previously described (Fontana et al., 2015). Briefly, lentiviral particles 
were produced by simultaneous cotransfection of HEK293 cells with four 
plasmids using the lipid reagent Lipofectamine 2000 (InvitrogenTM, Thermo): 
the packaging construct (pMDLg/pRRE), the Rev-expressing construct 
(pRSV- Rev) (Addgene, Plasmid numbers #12251, #12253) (Dull et al., 
1998), the transfer vector pLV-PLK-GFP (Prieto et al., 2011) and the Rabies 
Virus glycoprotein (PV strain, using the pZC-GlycoG construct developed in 
our laboratory). 48 h after transfection the supernatant was harvested, 












−80°C prior to use. For the RVNA measurement test, serial 2-fold dilutions of 
sera in 50 μl of DMEM medium, using 96-well micro-plates, were made. After 
that, 50 μl of lentivirus supernatant, with a titer of 1×106 TU ml−1, was added 
and incubated for 1 h at 37°C. Finally, 3.5×103 HEK293 cells in a final volume 
of 50 μl were added. Plates were incubated for 72 h at 37°C and the 
percentage of fluorescent cells measured by flow cytometry. The 
concentration of RVNA was calculated using the World Health Organization 
2nd International Standard for anti-rabies immunoglobulin (NIBSC) as 
standard. This reference preparation contains 30 IU.ml−1 human anti-rabies 
immunoglobulin and is recommended for RVNA measurement. 
 
7. Rabies vaccine NIH potency test 
The NIH potency test (Wilbur and Aubert, 2016) was performed in order to 
analyse the potency of VLPs samples as follows: CF-1 mice were injected 
intraperitoneally at days 0 and 7 with 0.5 ml of experimental or international 
reference vaccine dilutions (1:5; 1:25, 1:125, 1:625 in PBS). At day 14, mice 
were intracerebrally challenged with 0.03 ml of a dilution of the virus standard 
strain (CVS strain) containing 25 LD50 and observed for 14 days. Mortality 




1. Rabies G protein expression analysis by confocal microscopy 
The adhP2E5 clone (Fontana et al., 2015) was thawed from the working cell 
bank stored in liquid nitrogen and analysed by confocal microscopy in order 
to confirm the correct subcellular localization of the G protein (Fig. 1). As 
shown in Fig. 1, G protein was specifically detected in the external membrane 
of the producer cells. This analysis is important due to the fact that in the 
RV-VLPs structure the G protein is anchored in the membrane and exposed 
in the particle surface (Fontana et al., 2015). 
 
2. RV-VLPs characterization  
RV-VLPs produced by adhP2E5 were purified by density gradient 
ultracentrifugation and characterized by transmission electron microscopy 
(TEM) (Fig. 2). Only one band in discontinuous iodixanol gradient was 
observed and enveloped round shaped particles were observed in TEM 
assays. 
 
3. RV-VLPs production using roller bottles 
To investigate the feasibility of using roller bottles as a method for the 
production of RV-VLPs we seeded 850 cm2 roller bottles with an exponential 
growth adhP2E5 cell culture. Medium exchange was performed every 48 h 
during the first 13 days and every 24 h during the last 5 days. RV-VLPs were 












obtained a total harvest of 2.5 L per bottle that was pooled and analysed by 
sandwich ELISA, presenting a glycoprotein content of 19 EU.ml-1. 
 
4. RV-VLPs immunogenicity analysis 
In order to analyse the immunogenic characteristics of the RV-VLPs 
produced in the roller bottles, we injected mice with the VLPs present in the 
clarified pool harvest, without adjuvant addition or any concentration step. In 
a control group, we immunized the animals with a commercial rabies 
veterinary vaccine, based on inactivated rabies virus adsorbed on aluminium 
hydroxide. 10 days after the second dose mice were bled and the recovered 
sera analysed by indirect ELISA in order to obtain total specific antibody 
titers. The results showed that the RV-VLPs produced in roller bottles were 
able to induce a specific immune response against rabies and that the 
humoral immune response triggered was similar to the induced by the 
commercial vaccine, without significant differences between groups (Fig. 4-
A). Besides, the RV-VLPs induced rabies virus neutralizing antibodies 
(RVNA) with a titer significantly higher than the one obtained using the 
inactivated virus vaccine (Fig. 4-B). This result demonstrate that this vaccine 
candidate could be a better antigen to produce RVNA, possibly due to that 
during the production of RV-VLPs there is no need to include inactivation 
processes like UV light treatment or chemical compounds like beta-
propiolactone. It has been described that inactivation steps reduce the 
antigenicity of some viral proteins (Chowdhury et al., 2015; Dembinski et al., 
2014; Jonges et al., 2010; RWEYEMAMU et al., 2016), normally because the 
conformational structure is affected. As neutralizing antibodies recognize 
external viral proteins, as is the case of the rabies virus glycoprotein which is 
organized as a trimer on the virion surface, if that structure is altered the 
induction of RVNA could be reduced. Anyway, the total specific antibodies 
titer shows similar results. 
Further, the titer of RVNA was studied over time (Fig. 5), demonstrating that 
RV-VLPs produced in adherent condition using roller bottles are able to 
induce a long-lasting antibody response. This is particularly important for 
rabies because a minimum titer of 0.5 IU.ml-1 is needed to demonstrate 
protection or a correct vaccination (Moore and Hanlon, 2010). The immune 
response triggered with RV-VLPs maintained high titers for more than 200 
days after vaccination. 
 
5. NIH potency test for rabies vaccine 
Finally, the VLPs harvest produced in roller bottles, without the addition of 
adjuvant or any concentration step, was analysed by the NIH potency test the 
gold-standard assay to measure the potency of rabies vaccine. We obtained 
a potency of 1 IU/ml, demonstrating that this recombinant vaccine candidate 
is not only able to induce a potent antibody response but also to induce the 














In the present work we evaluated the possibility of using an adherent 
mammalian cell line stably expressing highly immunogenic RV-VLPs in a 
roller bottles, in order to show that this technology could be applied in the 
rabies veterinary vaccine production industry. 
Rabies vaccine has a central role in the prevention and treatment of the 
disease. Both pre and post-exposure prophylaxis in humans are based on the 
administration of the vaccine. On the other hand, vaccination of pets and 
stray animals through mass vaccination campaigns is the chosen strategy of 
the international health authorities to eliminate dog-transmitted human rabies 
(Wallace et al., 2017). The most affected countries by human rabies are 
placed in Asia and Africa, where more than 97% of the cases are related with 
dog bites, whereas in some countries of Latin America and the Caribbean 
dog rabies is still being endemic.  
In some countries nerve tissue vaccines remain in production although its 
replacement is highly recommended by the WHO (WHO, 2018). Moreover, in 
the production of cell culture-based vaccines two differential stages have to 
be performed. The first one involves the cell growing phase and no 
production is achieved. Once the desired cell concentration is obtained the 
culture is infected and the productive phase starts. Thus, only half of the 
overall process is indeed productive, so the obtained doses have to be 
related with the entire amount of medium that was used during all the batch 
culture, including the cell expansion stage. Conversely, in the case of the 
production of RV-VLPs using our the stable HEK293 clone (Fontana et al., 
2014), the entire culture time is productive so all the harvest contains VLPs, 
even in the first days after the culture seed (Fig. 3). This feature gives to this 
platform an important advantage over the classical virus production due to 
the fact that the cell expansion phase is not needed and there is no culture 
medium consumption without production.  
Besides, we propose the use of the roller bottle method as it is one of the 
best-established static systems for the production of vaccines. Due to the 
simplicity and robustness of this system, some vaccines manufacturing 
processes still rely on this culture system (Gallo-Ramirez et al., 2015), even 
for rabies. The possibility of changing the culture platform based on 
inactivated viral vaccines produced in BHK-21 by the use of this RV-VLPs 
production platform could be a simple solution for companies that are already 
producing the veterinary vaccine in roller bottles and are looking forward to 
reduce costs and moreover, as there is no need of manipulating the rabies 
virus, making the process safer and avoiding laborious work to maintain and 
validate viral seeds stocks. On the other hand, there is no need of an 
inactivation step and therefore no risk of incomplete inactivation or any 
residual viral activity. Besides, as our results show, RV-VLPs injected without 
adjuvant addition induce an excellent and long-lasting antibody response with 
potency values similar to the commercial veterinary vaccine that is formulated 












make the process simpler. It is known that manipulation of roller bottles 
carries relatively high sterility risk, when performing medium exchange and 
harvest but, on the other hand, in comparison to bioreactors, static systems 
require a lower operator skill level and lower investment costs, making their 
implementation at large scale still an affordable and competitive option for 
manufacturers with reduced facility complexity (Heldens et al., 2008; Gallo-
Ramírez et al., 2015).  
 
Conclusions 
In conclusion, we have demonstrated that RV-VLPs can be stably produced 
in roller bottles with an interesting overall productivity due to the fact that 
during all the culture process the VLPs are being produced and secreted to 
the supernatant. We have shown that these RV-VLPs are able to induce a 
specific antibody response when injected without adjuvant with a , slightly 
higher RVNA titer in comparison with the induced by the commercial rabies 
vaccine. Further, this RVNA response was maintained over time with titers 
above the limit of 0.5 IU.ml-1, which indicates an adequate vaccination (Moore 
and Hanlon, 2010). Finally, the NIH potency test showed the required value 
for veterinary rabies vaccines, demonstrating that the RV-VLPs produced in 
this cell platform are able to confer protection against rabies virus challenge.  
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Confocal microscopy of adhP2E5 clone. Cells were fixed, incubated with anti-
G protein monoclonal antibody and then incubated with goat anti-mouse 
AlexaFluor 488® conjugated antibody. Nuclei were stained with TO-PRO™-3 
Iodide. Merge image is shown. 
 
Figure 2 
RV-VLPs characterization. A. VLPs band obtained in the density gradient 














Production of RV-VLPs in a roller bottle platform. Cells were seed and 
incubated during 18 days. Supernatant was harvest and the medium 
exchanged every 48 h during the first 13 days and every 24 h during the last 
5 days. Each harvest was analysed by ELISA sandwich and the RV-VLPs 
concentration was measured. 
 
Figure 4. Humoral immune response triggered by RV-VLPs in mice. 10 days 
after second dose sera of animals was analysed. A. Total specific antibody 












were quantified by pseudotyped lentivirus assays in vitro. Results are 
expressed as mean ± SEM. 
 
Figure 5. Rabies virus neutralizing antibodies over time. Sera from vaccinated 
mice (n=6) were obtained at days 17, 47, 147 and 210, and analysed by 
pseudotyped lentivirus assay. Dotted line indicate a titer of 0,5 IU.ml-1.  
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